Employees: 1,116
Size Eckert & Ziegler (EUZ.DE) is a Germany Health Care company (Medical Specialties) with a market value of $1.03B, the 140th largest of 198 Germany companies the cockpit tracks. Shares closed at €14.98 on 18 Nov 2026.
Performance Over six months the shares fell 2.3%, against -7.9% for the median peer and -0.9% for the Germany market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 4.0% over the last twelve months (peer median +12.3%); the operating margin is 25.7% (peer median 10.3%).
Valuation It trades at 18.5× forward earnings against a peer median of 18.4× (7th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 17.2 points above its cost of capital (10.7% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €317M | €312M | €296M | €246M | €222M |
| Revenue growth | — | +5% | +20% | +11% | — |
| Gross profit | €157M | €147M | €138M | €111M | €102M |
| EBITDA | €98.6M | €92.1M | €78.7M | €64.5M | €57.8M |
| Net income | €54.3M | €48.8M | €33.3M | €26.3M | €29.3M |
| Free cash flow | €28.7M | €34.4M | €50.4M | €20.7M | €5.92M |
| Capital expenditure | €22.8M | €26.0M | €17.2M | €26.3M | €27.1M |
| Total debt | €38.7M | €44.8M | €55.3M | €56.3M | €49.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EUZ.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.5% | -5.1% | 2nd highest of 21 |
| 6-month return | -2.3% | -7.9% | 8th highest of 20 |
| Distance from 52-week high | -11.1% | -28.9% | 3rd highest of 21 |
| Revenue growth (TTM) | +4.0% | +12.3% | 6th lowest of 19 |
| Operating margin | 25.7% | 10.3% | 6th highest of 20 |
| Forward P/E | 18.5× | 18.4× | 7th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | 7.7% | 5.9% | 6th most demanding of 14 |
| Growth delivered (Del g) | +12.1% | +10.4% | 6th highest of 14 |
| Hurdle (Req g minus delivered) | -4.4 pp | -3.0 pp | 6th least demanding of 14 |
| ROIC minus cost of capital | +17.2 pp | +2.9 pp | 6th highest of 19 |
| EV / EBITDA | 8.7× | 9.5× | 5th cheapest of 10 |
| Net debt / EBITDA | -0.8× | 0.0× | 4th least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 18.5× | 7.7% | +12.1% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | n/a | 57.7% | +40.6% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | n/a | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | n/a | 50.8% | +8.6% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 7.5× | -4.0% | +3.5% |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 19.3× | 4.9% | +10.4% |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% | +21.5% |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 18.0× | 6.9% | -2.9% |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | n/a | n/a | n/a |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | n/a | n/a | n/a |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | n/a | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% | +8.8% |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 50.3× | 10.7% | +12.9% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% | +3.6% |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% | +34.5% |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | n/a | n/a | n/a |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 15.1× | n/a | n/a |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 19.9× | 3.3% | +13.9% |
| JINS 3046.T | Japan | $963M | -8% | +14% | 10% | 18.7× | -6.1% | +11.7% |
| Safilo SFL.MI | Italy | $953M | +42% | -4% | 9% | 15.8× | 1.3% | +4.7% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |